Edwards Lifesciences Corporation
NYSEEdwards Lifesciences heads into its May 7 Q1 2026 results with analysts tilting bullish after a flurry of target increases — but the debate is sharpening around whether the company can defend its operating margins while sustaining double-digit TMTT growth. The post-earnings analyst response to Q4 has been notably constructive. Barclays raised its target to $110, maintaining…
Snapshot as of 7 May 2026
Edwards Lifesciences heads into its May 7 Q1 2026 results with analysts tilting bullish after a flurry of target increases — but the debate is sharpening around whether the company can defend its operating margins…
Edwards Lifesciences arrives at its Q1 2026 earnings release — due after the close today — with the most notable story running in the bears' retreat, not their advance. Short interest has dropped sharply over the past…
Edwards Lifesciences reports Q1 2026 results Wednesday after market close. The medical device maker posts earnings as short interest has declined 19% over the past week to 1.72% of float. Short sellers have backed away…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for EW — free to start on ORTEX.
Sign up for free →Open EW on ORTEX